Clinical Psychiatry News - Texas depresses Zyprexa
The Texas Medicaid agency announced that it will not include the atypical antipsychotic Zyprexa (olanzapine) on its preferred drug list. To prescribe Zyprexa to Medicaid patients, physicians will now have to get prior authorization from the agency. Texas, similar to many other states, is facing budget constraints; Zyprexa accounted for $86 million of Texas Medicaid’s $1.9 billion in drug spending last year.
Related Results
Injectable ZyprexaZyprexa WarningZyprexa filingZyprexa unveiledZyprexa patent upheld
Zyprexa is a big seller for Eli Lilly, accounting for $4.3 billion of its $12.6 billion in sales last year. Several other states, including Kentucky and West Virginia, have also excluded Zyprexa from their preferred drug lists. Opponents of these moves say that each patient responds differently to different medications and that Zyprexa may be the best drug in some cases. Patients currently stabilized on Zyprexa can continue receiving it without prior authorization.
COPYRIGHT 2004 International Medical News Group
COPYRIGHT 2008 Gale, Cengage Learning
